Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Denosumab (Prolia, Xgeva) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Denosumab (Prolia, Xgeva) Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Denosumab (Prolia)
4.4.1. Denosumab (Prolia), 2021 - 2033 (USD Million)
4.5. Denosumab (Xgeva)
4.5.1. Denosumab (Xgeva) Market, 2021 - 2033 (USD Million)
4.6. Biosimilars
4.6.1. Biosimilars Market, 2021 - 2033 (USD Million)
Chapter 5. Denosumab (Prolia, Xgeva) Market: Indication Business Analysis
5.1. Indication Market Share, 2024 & 2033
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
5.4. Osteoporosis
5.4.1. Osteoporosis, 2021 - 2033 (USD Million)
5.5. Bone Loss due to Hormone Ablation
5.5.1. Bone Loss due to Hormone Ablation Market, 2021 - 2033 (USD Million)
5.6. Bone Metastases from Solid Tumors
5.6.1. Bone Metastases from Solid Tumors Market, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Denosumab (Prolia, Xgeva) Market: End User Business Analysis
6.1. End User Market Share, 2024 & 2033
6.2. End User Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
6.4. Hospitals & Oncology Centers
6.4.1. Hospitals & Oncology Centers Market, 2021 - 2033 (USD Million)
6.5. Specialty Clinics / Endocrinology Centers
6.5.1. Specialty Clinics / Endocrinology Centers, 2021 - 2033 (USD Million)
Chapter 7. Denosumab (Prolia, Xgeva) Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.5. Europe
7.6. Asia Pacific
7.7. Latin America
7.8. Middle East and Africa
Chapter 8. Competitive Landscape
8.1. Company Profile
8.1.1. Amgen Inc.
8.1.1.1. Overview
8.1.1.2. Financial Performance
8.1.1.3. Strategic Mapping
8.2. Concurrent Competitive Landscape
8.2.1. Sandoz AG
8.2.1.1. Overview
8.2.1.2. Financial Performance
8.2.1.3. Product Benchmarking
8.2.1.4. Strategic Mapping
8.2.2. Fresenius Kabi AG
8.2.2.1. Overview
8.2.2.2. Financial Performance
8.2.2.3. Product Benchmarking
8.2.2.4. Strategic Mapping
8.2.3. Celltrion Inc.
8.2.3.1. Overview
8.2.3.2. Financial Performance
8.2.3.3. Product Benchmarking
8.2.3.4. Strategic Mapping
8.2.4. Biocon Biologics Ltd.
8.2.4.1. Overview
8.2.4.2. Financial Performance
8.2.4.3. Product Benchmarking
8.2.4.4. Strategic Mapping
8.2.5. Henlius Biotech Inc.
8.2.5.1. Overview
8.2.5.2. Financial Performance
8.2.5.3. Product Benchmarking
8.2.5.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Denosumab (Prolia, Xgeva) market, by region, 2021 - 2033 (USD Million)
Table 4 North America Denosumab (Prolia, Xgeva) market, by Product, 2021 - 2033 (USD Million)
Table 5 North America Denosumab (Prolia, Xgeva) market, by Indication, 2021 - 2033 (USD Million)
Table 6 North America Denosumab (Prolia, Xgeva) market, by End User, 2021 - 2033 (USD Million)
Table 7 Europe Denosumab (Prolia, Xgeva) market, by Product, 2021 - 2033 (USD Million)
Table 8 Europe Denosumab (Prolia, Xgeva) market, by Indication, 2021 - 2033 (USD Million)
Table 9 Europe Denosumab (Prolia, Xgeva) market, by End User, 2021 - 2033 (USD Million)
Table 10 Asia Pacific Denosumab (Prolia, Xgeva) market, by Product, 2021 - 2033 (USD Million)
Table 11 Asia Pacific Denosumab (Prolia, Xgeva) market, by Indication, 2021 - 2033 (USD Million)
Table 12 Asia Pacific Denosumab (Prolia, Xgeva) market, by End User, 2021 - 2033 (USD Million)
Table 13 Latin America Denosumab (Prolia, Xgeva) market, by Product, 2021 - 2033 (USD Million)
Table 14 Latin America Denosumab (Prolia, Xgeva) market, by Indication, 2021 - 2033 (USD Million)
Table 15 Latin America Denosumab (Prolia, Xgeva) market, by End User, 2021 - 2033 (USD Million)
Table 16 Middle East & Africa Denosumab (Prolia, Xgeva) market, by Product, 2021 - 2033 (USD Million)
Table 17 Middle East & Africa Denosumab (Prolia, Xgeva) market, by Indication, 2021 - 2033 (USD Million)
Table 18 Middle East Denosumab (Prolia, Xgeva) market, by End User, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Denosumab (Prolia, Xgeva) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market End User & validation
Fig. 8 Market snapshot
Fig. 9 Product outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Denosumab (Prolia, Xgeva) market dynamics
Fig. 12 Denosumab (Prolia, Xgeva) market: Porter’s five forces analysis
Fig. 13 Denosumab (Prolia, Xgeva) market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Denosumab (Prolia), 2021 - 2033 (USD Million)
Fig. 16 Denosumab (Xgeva) market, 2021 - 2033 (USD Million)
Fig. 17 Biosimilar market, 2021 - 2033 (USD Million)
Fig. 18 Indication market, 2021 - 2033 (USD Million)
Fig. 19 Osteoporosis market, 2021 - 2033 (USD Million)
Fig. 20 Bone Loss due to Hormone Ablation market, 2021 - 2033 (USD Million)
Fig. 21 Bone Metastases from Solid Tumors market, 2021 - 2033 (USD Million)
Fig. 22 Others market, 2021 - 2033 (USD Million)
Fig. 23 End User market, 2021 - 2033 (USD Million)
Fig. 24 Hospitals & Oncology Centers market, 2021 - 2033 (USD Million)
Fig. 25 Specialty Clinics / Endocrinology Centers market, 2021 - 2033 (USD Million)
Fig. 26 Denosumab (Prolia, Xgeva) market revenue, by region
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 North America Denosumab (Prolia, Xgeva) market, 2021 - 2033 (USD Million)
Fig. 29 Europe Denosumab (Prolia, Xgeva) market, 2021 - 2033 (USD Million)
Fig. 30 Asia Pacific Denosumab (Prolia, Xgeva) market, 2021 - 2033 (USD Million)
Fig. 31 Latin America Denosumab (Prolia, Xgeva) market, 2021 - 2033 (USD Million)
Fig. 32 MEA Denosumab (Prolia, Xgeva) market, 2021 - 2033 (USD Million)
Fig. 33 Company categorization
Fig. 34 Company market position analysis
Fig. 35 Strategic framework
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
